Martin Lagging

Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype

Ranjit Ray, Martin Lagging, Keith Meyer et al. · Journal of Virology · 1996 · 407 citations · Full text

Viral Replication, Hepatitis C Virus, Immunology +17

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

Eric Lawitz, Edward Gane, Brian L. Pearlman et al. · The Lancet · 2014 · 299 citations

Open-label Phase 2, Hepatology, Hepatitis C +10

Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients

Johan Westin, Hans Nordlinder, Martin Lagging et al. · Journal of Hepatology · 2002 · 277 citations

Hepatology, Autoimmune Disease, Hepatitis C +14

IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection

Martin Lagging, Ana I. Romero, Johan Westin et al. · Hepatology · 2006 · 213 citations

Immunology, Covid-19, Pretreatment Ip-10 Analysis +16

Interferon (IFN)–γ–Inducible Protein–10: Association with Histological Results, Viral Kinetics, and Outcome during Treatment with Pegylated IFN‐α2a and Ribavirin for Chronic Hepatitis C Virus Infection

Ana I. Romero, Martin Lagging, Johan Westin et al. · The Journal of Infectious Diseases · 2006 · 213 citations · Full text